Evaluating nicorandil's effects on obese patients with type 2 diabetes
Clinical Study Evaluating the Effect of Nicorandil in Type 2 Diabetic Obese Patients Treated With Sulfonylurea
This study tests if the medication nicorandil can help obese people with type 2 diabetes better control their blood sugar and manage their weight while they are already taking other diabetes medications.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 46 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta) |
| Trial ID | NCT06423729 on ClinicalTrials.gov |
What this trial studies
This study evaluates the impact of nicorandil on glycemic control and body weight in obese patients with type 2 diabetes who are currently treated with sulfonylureas. It aims to determine whether nicorandil can improve blood sugar levels and assist in weight management for this specific patient population. The study will involve administering nicorandil at a dosage of 10 mg to eligible participants over a defined period. The research is designed to gather data on both metabolic and weight-related outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 60 with a BMI over 30 who have been diagnosed with type 2 diabetes for 1 to 10 years and are currently treated with sulfonylureas.
Not a fit: Patients who are pregnant, have severe renal or hepatic disease, or are hypersensitive to nicorandil will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option that improves glycemic control and aids in weight loss for obese patients with type 2 diabetes.
How similar studies have performed: While there may be limited data on nicorandil specifically for this population, similar studies exploring the effects of medications on glycemic control and weight in diabetic patients have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diabetes duration ranged from 1 to 10 years. * Body mass index (BMI) \>30 Kg/m2. * The selected patients are treated with sulfonylureas alone. * The age of selected patient ranged from 18 and 60 years. Exclusion Criteria: * Pregnant and lactating females. * Patients with hypersensitivity to nicorandil. * Uncontrolled hypertension and its antihypertensive medications * Severe renal or hepatic disease.
Where this trial is running
Tanta
- Faculty of Pharmacy, Tanta University — Tanta, Egypt (Recruiting)
Study contacts
- Study coordinator: Merna Mohamed Seddik Ali
- Email: merna198ali@gmail.com
- Phone: +201026064628
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.